keyword
MENU ▼
Read by QxMD icon Read
search

Arimoclomol

keyword
https://www.readbyqxmd.com/read/27605553/heat-shock-protein-based-therapy-as-a-potential-candidate-for-treating-the-sphingolipidoses
#1
Thomas Kirkegaard, James Gray, David A Priestman, Kerri-Lee Wallom, Jennifer Atkins, Ole Dines Olsen, Alexander Klein, Svetlana Drndarski, Nikolaj H T Petersen, Linda Ingemann, David A Smith, Lauren Morris, Claus Bornæs, Signe Humle Jørgensen, Ian Williams, Anders Hinsby, Christoph Arenz, David Begley, Marja Jäättelä, Frances M Platt
Lysosomal storage diseases (LSDs) often manifest with severe systemic and central nervous system (CNS) symptoms. The existing treatment options are limited and have no or only modest efficacy against neurological manifestations of disease. We demonstrate that recombinant human heat shock protein 70 (HSP70) improves the binding of several sphingolipid-degrading enzymes to their essential cofactor bis(monoacyl)glycerophosphate in vitro. HSP70 treatment reversed lysosomal pathology in primary fibroblasts from 14 patients with eight different LSDs...
September 7, 2016: Science Translational Medicine
https://www.readbyqxmd.com/read/27273088/induction-of-heat-shock-proteins-in-differentiated-human-neuronal-cells-following-co-application-of-celastrol-and-arimoclomol
#2
Catherine A S Deane, Ian R Brown
Few effective therapies exist for the treatment of neurodegenerative diseases that have been characterized as protein misfolding disorders. Upregulation of heat shock proteins (Hsps) mitigates against the accumulation of misfolded, aggregation-prone proteins and synaptic dysfunction, which is recognized as an early event in neurodegenerative diseases. Enhanced induction of a set of Hsps in differentiated human SH-SY5Y neuronal cells was observed following co-application of celastrol and arimoclomol, compared to their individual application...
September 2016: Cell Stress & Chaperones
https://www.readbyqxmd.com/read/27009270/targeting-protein-homeostasis-in-sporadic-inclusion-body-myositis
#3
Mhoriam Ahmed, Pedro M Machado, Adrian Miller, Charlotte Spicer, Laura Herbelin, Jianghua He, Janelle Noel, Yunxia Wang, April L McVey, Mamatha Pasnoor, Philip Gallagher, Jeffrey Statland, Ching-Hua Lu, Bernadett Kalmar, Stefen Brady, Huma Sethi, George Samandouras, Matt Parton, Janice L Holton, Anne Weston, Lucy Collinson, J Paul Taylor, Giampietro Schiavo, Michael G Hanna, Richard J Barohn, Mazen M Dimachkie, Linda Greensmith
Sporadic inclusion body myositis (sIBM) is the commonest severe myopathy in patients more than 50 years of age. Previous therapeutic trials have targeted the inflammatory features of sIBM but all have failed. Because protein dyshomeostasis may also play a role in sIBM, we tested the effects of targeting this feature of the disease. Using rat myoblast cultures, we found that up-regulation of the heat shock response with arimoclomol reduced key pathological markers of sIBM in vitro. Furthermore, in mutant valosin-containing protein (VCP) mice, which develop an inclusion body myopathy, treatment with arimoclomol ameliorated disease pathology and improved muscle function...
March 23, 2016: Science Translational Medicine
https://www.readbyqxmd.com/read/26751860/molecular-basis-of-als-and-ftd-implications-for-translational-studies
#4
Rajka M Liščić
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative disorders, related by signs of deteriorating motor and cognitive functions, and short survival. The cause is unknown and no effective treatment currently exists. For ALS, there is only a drug Riluzole and a promising substance arimoclomol. The overlap between ALS and FTD occurs at clinical, genetic, and pathological levels. The majority of ALS cases are sporadic (SALS) and a subset of patients has an inherited form of the disease, familial ALS (FALS), with a common SOD1 mutation, also present in SALS...
December 2015: Arhiv za Higijenu Rada i Toksikologiju
https://www.readbyqxmd.com/read/24934355/potential-therapeutic-drugs-and-methods-for-the-treatment-of-amyotrophic-lateral-sclerosis
#5
G Yacila, Y Sari
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder caused by damage of motoneurons leading to paralysis state and long term disability. Riluzole is currently the only FDA-approved drug for the treatment of ALS. The proposed mechanisms of ALS include glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, protein aggregation, SOD1 accumulations, and neuronal death. In this review, we discuss potential biomarkers for the identification of patients with ALS. We further emphasize potential therapy involving the uses of neurotrophic factors such as IGFI, GDNF, VEGF, ADNF-9, colivelin and angiogenin in the treatment of ALS...
2014: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/24853414/the-heat-shock-response-co-inducer-arimoclomol-protects-against-retinal-degeneration-in-rhodopsin-retinitis-pigmentosa
#6
D A Parfitt, M Aguila, C H McCulley, D Bevilacqua, H F Mendes, D Athanasiou, S S Novoselov, N Kanuga, P M Munro, P J Coffey, B Kalmar, L Greensmith, M E Cheetham
Retinitis pigmentosa (RP) is a group of inherited diseases that cause blindness due to the progressive death of rod and cone photoreceptors in the retina. There are currently no effective treatments for RP. Inherited mutations in rhodopsin, the light-sensing protein of rod photoreceptor cells, are the most common cause of autosomal-dominant RP. The majority of mutations in rhodopsin, including the common P23H substitution, lead to protein misfolding, which is a feature in many neurodegenerative disorders. Previous studies have shown that upregulating molecular chaperone expression can delay disease progression in models of neurodegeneration...
2014: Cell Death & Disease
https://www.readbyqxmd.com/read/23978556/the-role-of-heat-shock-proteins-in-amyotrophic-lateral-sclerosis-the-therapeutic-potential-of-arimoclomol
#7
REVIEW
Bernadett Kalmar, Ching-Hua Lu, Linda Greensmith
Arimoclomol is a hydroxylamine derivative, a group of compounds which have unique properties as co-inducers of heat shock protein expression, but only under conditions of cellular stress. Arimoclomol has been found to be neuroprotective in a number of neurodegenerative disease models, including Amyotrophic Lateral Sclerosis (ALS), and in mutant Superoxide Dismutase 1 (SOD1) mice that model ALS, Arimoclomol rescues motor neurons, improves neuromuscular function and extends lifespan. The therapeutic potential of Arimoclomol is currently under investigation in a Phase II clinical trial for ALS patients with SOD1 mutations...
January 2014: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/23393146/co-induction-of-the-heat-shock-response-ameliorates-disease-progression-in-a-mouse-model-of-human-spinal-and-bulbar-muscular-atrophy-implications-for-therapy
#8
Bilal Malik, Niranjanan Nirmalananthan, Anna L Gray, Albert R La Spada, Michael G Hanna, Linda Greensmith
Spinal and bulbar muscular atrophy, also known as Kennedy's disease, is an adult-onset hereditary neurodegenerative disorder caused by an expansion of the polyglutamine repeat in the first exon in the androgen receptor gene. Pathologically, the disease is defined by selective loss of spinal and bulbar motor neurons causing bulbar, facial and limb weakness. Although the precise disease pathophysiology is largely unknown, it appears to be related to abnormal accumulation of the pathogenic androgen receptor protein within the nucleus, leading to disruption of cellular processes...
March 2013: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/22815892/plasma-neurofilament-heavy-chain-levels-correlate-to-markers-of-late-stage-disease-progression-and-treatment-response-in-sod1-g93a-mice-that-model-als
#9
Ching-Hua Lu, Axel Petzold, Bernadett Kalmar, James Dick, Andrea Malaspina, Linda Greensmith
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disorder characterised by progressive degeneration of motor neurons leading to death, typically within 3-5 years of symptom onset. The diagnosis of ALS is largely reliant on clinical assessment and electrophysiological findings. Neither specific investigative tools nor reliable biomarkers are currently available to enable an early diagnosis or monitoring of disease progression, hindering the design of treatment trials...
2012: PloS One
https://www.readbyqxmd.com/read/22591194/treatment-with-a-coinducer-of-the-heat-shock-response-delays-muscle-denervation-in-the-sod1-g93a-mouse-model-of-amyotrophic-lateral-sclerosis
#10
Bernadett Kalmar, Emem Edet-Amana, Linda Greensmith
We undertook a longitudinal study of the histological and biochemical changes at the neuromuscular junction (NMJ) in muscles of SOD1-G93A mice. We also assessed these functions in mice treated with a known heat shock protein inducer, arimoclomol. Tissue samples of treated and untreated mSOD mice were analysed for AChE and ChAT enzyme activities as markers of neuromuscular function. Sections of hindlimb muscles (TA, EDL and soleus) were also stained for succinate dehydrogenase and silver cholinesterase activities as well as for immunohistochemistry...
June 2012: Amyotrophic Lateral Sclerosis
https://www.readbyqxmd.com/read/21445803/a-heat-shock-protein-co-inducer-treatment-improves-behavioral-performance-in-rats-exposed-to-hypoxia
#11
Kui Xu, Xiaoyan Sun, Bernadette O Erokwu, Ibolja Cernak, Joseph C Lamanna
We investigated the effect of a heat-shock protein co-inducer, arimoclomol (CytRx, LA, CA), on hypoxia-adaptive responses using a rat model of simulated altitude exposure (hypobaric hypoxia).Cognitive function was measured using a T-maze and an object recognition test.Motor function was measured using an inclined-screen test and an adhesion removal test. Immunohistochemical analyses were assessed in brain for heat-shock protein 70 (HSP 70), intercellular adhesion molecule 1 (ICAM- 1) and apoptosis (TUNEL staining)...
2011: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/20582873/arimoclomol-a-coinducer-of-heat-shock-proteins-for-the-potential-treatment-of-amyotrophic-lateral-sclerosis
#12
REVIEW
Julie Phukan
Recent years have seen an explosion of research into increasingly prevalent neurodegenerative diseases. Arimoclomol (BRX-220), being developed by CytRx Corp, is an oral therapeutic candidate for the treatment of amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease. ALS is a fatal, incurable disorder, which can present as sporadic (90 to 95% of cases) or familial (5 to 10% of cases) forms. The etiology of sporadic ALS remains unknown and much of the understanding of ALS pathogenesis has been derived through study of its familial forms; in particular, through study of autosomal dominant mutations in the SOD1 (copper/zinc superoxide dismutase) gene, which cause approximately 20% of familial ALS cases...
July 2010: IDrugs: the Investigational Drugs Journal
https://www.readbyqxmd.com/read/19938902/arimoclomol-a-potential-therapy-under-development-for-als
#13
REVIEW
Veena Lanka, Scott Wieland, Jack Barber, Merit Cudkowicz
Arimoclomol, an amplifier of heat shock protein expression involved in cellular stress response, has emerged as a potential therapeutic candidate in amyotrophic lateral sclerosis (ALS) in recent years. Treatment with arimoclomol was reported to improve survival and muscle function in a mouse model of motor neuron disease. Several single- and multiple-dose safety studies have been completed in healthy control subjects. A 3-month Phase IIa study in people with ALS demonstrated safety at dosages up to 300 mg/day and another study is currently recruiting participants with familial ALS caused by mutations in the superoxide dismutase gene...
December 2009: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/19183864/activation-of-the-heat-shock-response-in-a-primary-cellular-model-of-motoneuron-neurodegeneration-evidence-for-neuroprotective-and-neurotoxic-effects
#14
Bernadett Kalmar, Linda Greensmith
Pharmacological up-regulation of heat shock proteins (hsps) rescues motoneurons from cell death in a mouse model of amyotrophic lateral sclerosis. However, the relationship between increased hsp expression and neuronal survival is not straightforward. Here we examined the effects of two pharmacological agents that induce the heat shock response via activation of HSF-1, on stressed primary motoneurons in culture. Although both arimoclomol and celastrol induced the expression of Hsp70, their effects on primary motoneurons in culture were significantly different...
2009: Cellular & Molecular Biology Letters
https://www.readbyqxmd.com/read/18673445/late-stage-treatment-with-arimoclomol-delays-disease-progression-and-prevents-protein-aggregation-in-the-sod1-mouse-model-of-als
#15
Bernadett Kalmar, Sergey Novoselov, Anna Gray, Michael E Cheetham, Boris Margulis, Linda Greensmith
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motoneuron degeneration, resulting in muscle paralysis and death, typically within 1-5 years of diagnosis. Although the pathogenesis of ALS remains unclear, there is evidence for the involvement of proteasome dysfunction and heat shock proteins in the disease. We have previously shown that treatment with a co-inducer of the heat shock response called arimoclomol is effective in the SOD(G93A) mouse model of ALS, delaying disease progression and extending the lifespan of SOD(G93A) mice (Kieran et al...
October 2008: Journal of Neurochemistry
https://www.readbyqxmd.com/read/18551622/arimoclomol-at-dosages-up-to-300-mg-day-is-well-tolerated-and-safe-in-amyotrophic-lateral-sclerosis
#16
RANDOMIZED CONTROLLED TRIAL
Merit E Cudkowicz, Jeremy M Shefner, Elizabeth Simpson, Daniela Grasso, Hong Yu, Hui Zhang, Amy Shui, David Schoenfeld, Robert H Brown, Scott Wieland, Jack R Barber et al.
Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic analysis...
July 2008: Muscle & Nerve
https://www.readbyqxmd.com/read/17656567/heat-shock-proteins-and-protection-of-the-nervous-system
#17
REVIEW
Ian R Brown
Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate...
October 2007: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/16832072/neuroprotective-agents-for-clinical-trials-in-als-a-systematic-assessment
#18
REVIEW
B J Traynor, L Bruijn, R Conwit, F Beal, G O'Neill, S C Fagan, M E Cudkowicz
BACKGROUND: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. OBJECTIVE: To identify potential neuroprotective agents for testing in phase III clinical trials and to outline which data need to be collected for each drug. METHODS: The authors identified 113 compounds by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS...
July 11, 2006: Neurology
https://www.readbyqxmd.com/read/15034571/treatment-with-arimoclomol-a-coinducer-of-heat-shock-proteins-delays-disease-progression-in-als-mice
#19
Dairin Kieran, Bernadett Kalmar, James R T Dick, Joanna Riddoch-Contreras, Geoffrey Burnstock, Linda Greensmith
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 years of diagnosis. Although the specific etiology of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathology that are very similar to that seen in human ALS patients...
April 2004: Nature Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"